Latest neuroscience Stories

Constraint Therapy Australia offers a new intensive rehabilitation program to help people who have suffered a stroke as well as those with cerebral palsy and some other neurological conditions. Perth, Australia (PRWEB) June 18, 2013 A ground-breaking therapy service has been launched in Perth to offer stroke patients a new rehabilitation treatment. Constraint Therapy Australia celebrated its launch earlier this month and offers a new intensive rehabilitation program to help people who...

BOSTON, June 18, 2013 /PRNewswire-USNewswire/ -- A new study by the Center for Information & Study on Clinical Research Participation (CISCRP) shows significant improvement in public perceptions of clinical trial safety, trust in the motives of research professionals and appreciation for trial volunteers. The study also offers insights into participant behaviors including those who drop out of trials prematurely. The online study, conducted between January and March 2013 among a...

Data presented at ENDO 2013, the Endocrine Society's 95th Annual Meeting WASHINGTON, June 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional data today at ENDO 2013, the Endocrine Society's 95(th) Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms. This effect further confirms tasimelteon's potential to reset the master body clock and address the circadian desynchrony which is...

SEATTLE, June 17, 2013 /PRNewswire/ -- Everyone loves a summer break and people with Alzheimer's disease are no different. While taking a trip may not be feasible for many with dementia, another kind of getaway can be very enjoyable and beneficial to the individual and their families, experts say. A "memory vacation" to a favorite destination from the past is brought to the place of residence, whether in their long-time home or at a memory-care community. "A variety of stimuli can...

CAMBRIDGE, Mass., June 17, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) will hold its 11(th) annual Tri-State Trek charity cycling event on July 19-21, 2013. The Tri-State Trek is a three-day, 270 mile bike ride from Newton, MA to Greenwich, CT with the mission to end amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO) Beginning in Newton, MA, the Tri-State Trek passes through...

The CogniFit brain fitness website is now available in 12 languages and in more than 65 countries. New York, NY (PRWEB) June 13, 2013 CogniFit, a leading developer of scientific brain training and online brain games, announces the release of its online brain fitness platform in Russian, offering its cognitive programs to over 250 millions new potential users who speak Russian in the world. The CogniFit brain fitness website is now available in more than 65 countries and in 12 different...

Allegheny General Hospital physicians recently used deep brain stimulation (DBS) to boost the metabolism of morbidly obese patients in a pilot study. Future expanded studies will explore whether DBS could help reduce cravings and curb appetite in that patient population. Berlin (PRWEB) June 13, 2013 The first use of deep brain stimulation to the brain’s “feeding center” was associated with a weight loss trend in morbidly obese patients, according to a pilot study presented today by...

Slowdowns in the transport and delivery of nutrients, proteins and signaling molecules within nerve cells may contribute to the development of the neurodegenerative disorder ALS, according to researchers at the University of Illinois at Chicago College of Medicine. The researchers showed how a genetic mutation often associated with inherited ALS caused delays in the transport of these important molecules along the long axons of neurons. Their findings were published in the online...

Decision does not impact other Lilly Alzheimer's compounds in development INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the progression of Alzheimer's disease. The decision to terminate the study was due to abnormal liver biochemical tests. Clinical study investigators have...

April Flowers for redOrbit.com - Your Universe Online A significant and potentially pivotal difference between the brains of patients with an inherited form of Alzheimer's disease and healthy family members who do not have it has been measured by researchers at Washington University School of Medicine in St. Louis. Researchers have long known that a protein fragment called amyloid beta builds up into plaques in Alzheimer’s patient’s brains. The theory is that these plaques cause the...